Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01939600
Other study ID # GIL-1322
Secondary ID
Status Completed
Phase N/A
First received August 29, 2013
Last updated November 17, 2014
Start date September 2013
Est. completion date August 2014

Study information

Verified date November 2014
Source St. Michael's Hospital, Toronto
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Dietary fiber is a type of carbohydrate which is not digested in the human small intestine. Whole grains are a source of dietary fiber that are used to promote health; however, using whole grains in commercial products results in a different taste and/or texture than the usual products made from refined grains. Thus, other types of high-fiber ingredients have been developed which can be incorporated into food products with less effect on their taste and/or texture. An example of this is resistant starch, defined as starch which is not digested in the human small intestine. The digestibility of starch is usually determined in-vitro; however, there is evidence that such methods may overestimate the amount of resistant starch by as much as 100%. The measurement of the amount of carbohydrate in the ileal effluent, digestive waste, of subjects with an ileostomy is considered to be the best in-vivo method of starch digestibility. The subjects collect ileal effluent during the day during which time they consume a polysaccharide-free diet. There is evidence that resistant starch consumed at breakfast is completely recovered in ileal effluent 8-10hr after consumption. The purpose of this study will be to compare the carbohydrate content recovered in ileal effluent of 10 subjects with a conventional ileostomy.


Description:

Dietary fiber consists mainly of carbohydrates which are not digested in the human small intestine. A high intake of dietary fiber is associated with many health benefits including, but not limited to, improved bowel function and reduced risk of weight gain, cardiovascular disease and diabetes. Therefore, there is great interest in the food industry to produce products enriched with dietary fiber to promote health. One way to achieve this is to use more whole grains (wheat, rice, oats, barley) as ingredients in products such as breakfast cereals, breads and food bars. However, the use of whole grains results in products which have a different taste and/or texture than the usual products made from refined grains. Thus, other types of high-fiber ingredients have been developed which can be incorporated into food products with less effect on their taste and/or texture. Examples of such ingredients are inulin (an oligosaccharide containing fructose) and resistant starch. Resistant starch, defined as starch which is not digested in the human small intestine, is present in small amounts (2-5% of total starch) in many normal foods.

Starch is the most abundant energy containing nutrient in the human diet; it consists of 2 types of polysaccharides: amylose, is a linear polymer consisting of long chains of glucose molecules joined by 1-4 linkages; and amylopectin, a highly branched polymer consisting of long chains of glucose molecules joined by 1-4 linkages with numerous 1-6 linkage branch points. Most (70-80%) of the starch in normal starchy foods (eg. cereals and potatoes) is amylopectin. Amylopectin is highly digestible because its branched structure makes it readily able to gelatinize, the process whereby adjacent starch molecules swell and separate from each other under the influence of moist heat (ie. cooking). By contrast amylose is less digestible because its linear structure allows adjacent molecules to associate by hydrogen bonding which reduces their ability to gelatinize. Some types of commercially available resistant starch come from strains of corn which produce starch containing 70 to 100% amylose.

The digestibility of starch is usually determined in-vitro using methods involving digestion of the starch with α-amylase under pH and temperature conditions thought to mimick digestion in the human small intestine. However, there is evidence that such methods may overestimate the amount of resistant starch by as much as 100%. Methods used to estimate starch digestibility in-vivo include the breath hydrogen method and the measurement of the amount of carbohydrate in the ileal effluent of subjects with an ileostomy. The latter is considered to be the best in-vivo method which involves preparation of subjects with a polysaccharide-free diet the day before then consumption of the test carbohydrate with breakfast. Subjects collect ileal effluent during the day during which time they consume a polysaccharide-free diet. There is evidence that resistant starch consumed at breakfast is completely recovered in ileal effluent 8-10hr after consumption. The objective of this study is to determine the amount of carbohydrates in 3 commercially available starches (Hi-Maize® 260, Hylon® VII and Amioca corn starch) which escape digestion in the human small intestine.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date August 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- males or non-pregnant females with a conventional ileostomy

- clinically stable with no clinical evidence of malabsorption

Exclusion Criteria:

- short bowel syndrome

- acute exacerbation of inflammatory bowel disease

- prone to high output with change in diet

- ileostomy created less than 6 months from the first study visit

- subjects using medications which influence gastrointestinal motility or absorption

- any condition which might, in the opinion of Dr. Wolever or Dr. Kim either: 1) make participation dangerous to the subject or to others, or 2) affect the results

- subjects who cannot or will not comply with the experimental procedures

- food allergies of any kind

Study Design

Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label


Intervention

Other:
Starch-free breakfast
Starch-free breakfast alone
Hi-Maize 260
Starch-free breakfast plus 55.3g Hi-Maize 260
Hylon VII
Starch-free breakfast plus 56.9g Hylon VII
Amioca
Starch-free breakfast plus 56.4g amioca starch

Locations

Country Name City State
Canada Glycemic Index Laboratories, Inc. Toronto Ontario

Sponsors (5)

Lead Sponsor Collaborator
St. Michael's Hospital, Toronto Glycemic Index Laboratories, Inc, Ingredion Incorporated, Iowa State University, University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Amount of fiber in ileostomy effluent Fiber will be measured using fiber assay 2009.01 and expressed in grams. Up to 10 hours after starting to consume breakfast No
Other Amount of fiber in ileostomy effluent Fiber will be measured using fiber assay 991.43 and expressed in grams. Up to 10 hours after starting to consume breakfast No
Other Amount of starch in ileostomy effluent Starch will be measured by acid hydrolysis and expressed in grams. Up to 10 hours after starting to consume breakfast No
Primary Amount of carbohydrate in ileostomy effluent Carbohydrate in ileal effluent will be measured using by proximate analysis and expressed in grams. Up to 10 hours after starting to consume breakfast No
Secondary Amount of fiber in ileostomy effluent Fiber is measured using the Englyst method and expressed in grams. Up to 10 hours after starting to consume breakfast No
Secondary Amount of starch in ileostomy effluent Starch will be measured using the Megazyme assay and expressed in grams. Up to 10 hours after starting to consume breakfast No
See also
  Status Clinical Trial Phase
Terminated NCT03746353 - Early Closure Versus Conventional Closure in Postoperative Patients With Low Anteriresection for Rectal Cancer N/A
Completed NCT03331783 - Assessment of the Effect of Output on New Adhesives N/A
Completed NCT02920294 - Modulation of Microbial Composition in Ileostomy Patients N/A
Completed NCT02886455 - Evaluation of the Influence of Output on Skin Covered by Newly Developed Adhesives N/A
Completed NCT02517541 - A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products N/A
Completed NCT01957553 - Investigating the Safety and Performance of a New 2-piece Ostomy Product Compared With SenSura Click 2-piece N/A
Completed NCT01994876 - Investigation of Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy N/A
Terminated NCT01994863 - Safety and Performance Investigation of a New 1-piece Ostomy Product Compared to Standard of Care 1-piece in Subjects With Ileostomy Phase 2
Completed NCT03289013 - Assessement of the Peal Force Needed to Peel New Adhesives From the Skin N/A
Terminated NCT03416023 - Safety, Performance and Durability of the TIES® Implant in Patients Requiring a Permanent Ileostomy N/A
Completed NCT02997267 - Early Closure of Protective Ileostomy in Rectal Cancer Patients N/A
Recruiting NCT01880918 - A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing N/A
Completed NCT01957397 - Investigation of Three Newly Developed 2-piece Convex Base-plates in Subjects With Ileostomy N/A
Recruiting NCT04577456 - Chyme Reinfusion for Type 2 Intestinal Failure N/A
Terminated NCT03587519 - Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery N/A
Recruiting NCT03872271 - Is Diverting Loop Ileostomy Necessary in Completion Proctectomy With Ileal Pouch Anal- Anastomosis: A Multicentre, Randomized Study of the GETAID Chirurgie Group. IDEAL Trial N/A
Completed NCT04606004 - Perianal Maceration in Pediatric Ostomy Closure Patients N/A
Completed NCT02886403 - Evaluation of the Influence of Output on a Newly Develop Adhesive N/A
Recruiting NCT03424447 - Stimulation of the Efferent Loop Before Loop Ileostomy Closure Phase 2
Completed NCT03770078 - Assessment of New Enhanced Ostomy Device in Real-life Settings in Subjects Having a Stoma N/A